Scarica l'app Stockscreener
5.21
5.62%
-0.31
Pre-mercato:
5.05
-0.16
-3.07%
Precedente Chiudi:
$5.52
Aprire:
$5.48
Volume 24 ore:
1.03M
Relative Volume:
1.05
Capitalizzazione di mercato:
$356.25M
Reddito:
-
Utile/perdita netta:
$-297.11M
Rapporto P/E:
-1.0039
EPS:
-5.19
Flusso di cassa netto:
$-216.95M
1 W Prestazione:
-2.43%
1M Prestazione:
-7.46%
6M Prestazione:
-67.92%
1 anno Prestazione:
-51.26%
Intervallo 1D:
$5.15
$5.91
Intervallo di 1 settimana:
$5.15
$6.18
Portata 52W:
$5.15
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
5.21 | 356.25M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals stock hits 52-week low at $5.21 - Investing.com
(PHAT) Investment Analysis and Advice - Stock Traders Daily
Phathom Pharmaceuticals (PHAT) Expected to Announce Earnings on Thursday - MarketBeat
Cantor Fitzgerald Upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) to Strong-Buy - MarketBeat
Phathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on Thursday - Defense World
Phathom Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 - The Manila Times
Phathom Pharmaceuticals to Host Conference Call on March 6, 2025, for Fourth Quarter and Full Year 2024 Financial Results - Nasdaq
Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - StockTitan
How to Take Advantage of moves in (PHAT) - Stock Traders Daily
Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN
Cantor Fitzgerald Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Phathom spikes as Cantor Fitzgerald bullish on IP claims - MSN
Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Phathom stock gains after Cantor bullish view (PHAT:NASDAQ) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside - TipRanks
Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals With Overweight Rating, $23 Price Target - Marketscreener.com
Taking a Closer Look At Phathom Pharmaceuticals Inc (PHAT) Following Its Recent Trade - Knox Daily
Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis - MarketBeat
Stifel maintains $28 target on Phathom Pharmaceuticals stock - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Bought by Jennison Associates LLC - MarketBeat
Stifel maintains $28 target on Phathom Pharmaceuticals stock By Investing.com - Investing.com Canada
Phathom Pharmaceuticals Inc (PHAT) Stock: Assessing the Risk and Reward - The News Heater
The Future of Phathom Pharmaceuticals Inc: Analyzing PHAT - The InvestChronicle
Phathom Pharmaceuticals Inc [PHAT] CFO and CBO makes an insider sale of 6,583 shares worth $43371.0. - Knox Daily
Closing Strong: Phathom Pharmaceuticals Inc (PHAT) Ends at 5.63, Down -6.01 from Last Close - The Dwinnex
A stock that deserves closer examination: Phathom Pharmaceuticals Inc (PHAT) - US Post News
PHAT stock touches 52-week low at $6.06 amid market challenges - MSN
Further weakness as Phathom Pharmaceuticals (NASDAQ:PHAT) drops 12% this week, taking five-year losses to 81% - Simply Wall St
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.
Exclusive: Phathom's Next-Gen GI Treatments Take Center Stage at Major Biotech Conference - StockTitan
Trading (PHAT) With Integrated Risk Controls - Stock Traders Daily
Phathom Pharmaceuticals Stock: A Comprehensive Analysis of Recent Developments - The Digital Weekly
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells 7,886 Shares of Stock - MarketBeat
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 6,583 Shares of Stock - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 19,109 Shares - MarketBeat
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Yahoo Finance
(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily
Barclays PLC Buys 45,402 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.13%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):